TuHURA Biosciences (NASDAQ:HURA) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of TuHURA Biosciences (NASDAQ:HURA) from a sell rating to a hold rating in a research report sent to investors on Monday morning.

HURA has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, TuHURA Biosciences presently has a consensus rating of “Hold” and a consensus target price of $9.00.

TuHURA Biosciences Trading Down 4.4%

Shares of TuHURA Biosciences stock opened at $1.73 on Monday. The firm has a market capitalization of $105.05 million, a PE ratio of -3.46 and a beta of -0.33. The firm’s 50 day moving average is $1.32 and its 200 day moving average is $1.65. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $4.44.

Institutional Investors Weigh In On TuHURA Biosciences

Several hedge funds have recently added to or reduced their stakes in HURA. Vanguard Group Inc. increased its position in TuHURA Biosciences by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock valued at $5,629,000 after acquiring an additional 35,426 shares during the period. Geode Capital Management LLC lifted its holdings in shares of TuHURA Biosciences by 6.4% during the fourth quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock worth $501,000 after purchasing an additional 39,710 shares during the period. State Street Corp lifted its holdings in shares of TuHURA Biosciences by 4.9% during the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after purchasing an additional 13,594 shares during the period. Apollon Wealth Management LLC grew its stake in shares of TuHURA Biosciences by 15.8% in the third quarter. Apollon Wealth Management LLC now owns 133,526 shares of the company’s stock worth $331,000 after purchasing an additional 18,252 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in shares of TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after purchasing an additional 54,051 shares during the last quarter. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.